Meet the Companies
Domainex is a fully integrated drug discovery service company serving pharmaceutical, biotechnology, academic and patient foundations globally. Domainex was established in 2001 as a spin-out from UCL, Birkbeck (University of London) and The Institute of Cancer Research. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years.
Hypha solve drug metabolite synthesis issues using mammalian and microbial biotransformation expertise, making mg-g amounts of human oxidative metabolites and glucuronides. The technique also improves solubility at the lead optimization stage by hydroxylating via C-H bond activation and highlights the production of active metabolites for SAR investigation and IP protection.
IN-PART is a matchmaking platform for university-industry collaboration. It enables businesses to find, evaluate and connect with advances in science and technology from academics who are actively looking for strategic external partnerships. Utilising natural language processing and smart-matching algorithms, IN-PART connects university technology with the most relevant professionals in industry. IN-PART is currently host to a community of research professionals from 98 universities in Europe, Japan, Australasia, Canada and the USA, and 3000+ R&D professionals from over 800 businesses worldwide
Medical Realities utilises new technologies such as Virtual Reality, Augmented Reality and Artificial Intelligence to bring first class surgical training to anybody, anywhere in the world. We developed Medical Realities, a Virtual Reality Teaching and Training platform on VR devices, the first Virtual Reality task simulator. This ground-breaking technology allows us to deliver a unique learning experience, offering students, doctors, and surgeons the ability to view and learn from actual training operations, from the viewpoint of the training surgeon
Orchard Therapeutics is clinical-stage biotechnology company developing innovative gene therapies to transform the lives of patients with rare disorders. Orchard’s development programmes exploit the potential of autologous ex-vivo haematopoietic stem cell gene therapy to restore normal gene function in. This pioneering technology uses a sample of the patient’s own stem cells, which are modified with a functioning copy of the missing or faulty gene before being transplanted back into the patient’s body.